Neuropsychiatric aspects of Parkinson's disease (Q33832479)

29 July 2017

1 reference

title

Neuropsychiatric aspects of Parkinson's disease (English)

1 reference

29 July 2017

1 reference

Marsh L

1

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

41

1 reference

29 July 2017

1

1 reference

29 July 2017

15-23

1 reference

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Diagnostic criteria for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Symptoms and duration of the prodromal phase in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parkinson's disease: Clinical analysis of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Internal tremor in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Cognitive deficits in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Depression, intellectual impairment, and Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Coexisting dementia and depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Risk factors for nursing home placement in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

New and emerging therapies for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Mechanism of action of dopaminergic agents in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Classification of fluctuations in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Neurocognitive and psychosocial correlates of ventroposterolateral pallidotomy surgery in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Fetal nigral transplantation as a therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Psychiatric symptoms in Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Functional and pathophysiological models of the basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

The neuropathologic basis of different clinical subgroups of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Depression and Parkinson's disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Evidence for atypical depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Depression in Parkinson's disease: a quantitative and qualitative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Some psychological factors in Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Does levodopa alter depression and psychopathology in Parkinsonism patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Depression in Patients with Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parkinsonism and Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Altered serotonin metabolism in depressed patients with parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

The relationship of serotonin to depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Association of [3H]-imipramine and [3H]-paroxetine binding with the 5HT transporter in brain and platelets: relevance to studies in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Depression in Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Reliability, validity, and clinical correlates of apathy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Apathy is not depression

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Clinical and biochemical correlates of bradyphrenia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Psychosocial factors in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parkinson's disease and anxiety: comorbidity with depression

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Anxiety and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Anxiety disorders in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Autonomic failure, depression and anxiety in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

The locus ceruleus and anxiety disorders in demented and nondemented familial parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Anxiety and motor performance in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Cholinesterase inhibition in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Managing the neuropsychiatric symptoms of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Treatment of depression in Parkinson's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Interaction of fluoxetine and selegiline

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Desipramine in treatment of Parkinson's disease. A placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Bupropion in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Serotonergic dysfunction in depression associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Sertraline for the treatment of depression in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Increase of Parkinson disability after fluoxetine medication

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

Electroconvulsive therapy in Parkinson's disease and other movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2800%2971169-8

7 January 2021

10.1016/S0033-3182(00)71169-8

Identifiers

DOI

0 references

Fatcat ID

release_ygwxbrf24fgv7fyobsw4b42hfi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ygwxbrf24fgv7fyobsw4b42hfi

24 November 2022

mapped directly with Wikidata item

PubMed ID

10665264

1 reference

PubMed ID

10665264